Immune to Cancer: The CRI Blog
-
Dr. Robert Schreiber and Interferon Gamma
By redefining our understanding of the relationship between cancer and the immune system, Dr. Robert Schreiber has…
-
AACR19 Recap: Leveraging the Latest Science to Improve Clinical Care
AACR19 highlighted incredible advances in our efforts to leverage cutting-edge science in order to improve medical treatment for…
-
CRI-Funded Trial Reveals Promising Potential of Immunotherapy Combination in Metastatic Pancreatic Cancer
Interim data from a novel immunotherapy-chemotherapy combination that targets the CD40 and PD-1 pathways show promising anti-tumor…
-
IO360 2019 Preview: Collaboration, Investment, Clinical Trials, and Combinations
The fifth annual Immuno-Oncology 360° conference will be held on February 6-8, 2019 in New York City.
-
How Immunotherapy Is Making an Impact in Liver Cancer
We spoke with Bruno Sangro, MD, PhD, about the current treatment landscape for patients with liver cancer,…
-
Recapping the Third Annual Rational Combinations 360°
In September, experts across the immunology and immunotherapy spectrum convened in Philadelphia to discuss the latest advances…
-
30 Days of CRI Impact
Throughout Cancer Immunotherapy Month in June we’ll be highlighting the 30 most important CRI-funded breakthroughs.
-
Second CAR T Cell Immunotherapy Approved for Patients with Lymphoma
A second CAR T cell immunotherapy targeting the CD19 receptor was approved by the FDA for patients…
-
Advocating for Innovative Clinical Trial Design
Laura Pearce, CRI consultant and head of clinical alliances, participates in a clinical trials panel on platform…